focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
Morning all,
Turbulent few weeks but for me, SAR has leapt over a pivotal milestone this week with the positive news on SAD dosing and food study. Not long to wait for final readout and as Sadoldgit has highlighted, prospects look good on this front too. So surely that leaves the company in a much stronger position to attract finance as the pathway to commercialisation becomes shorter. Ditto, interest from prospective partners. As for the SP, I’ve always felt AIM is akin to a cowboy town without a sheriff ! The troughs and spikes, always exaggerated. IMO the SP is so disconnected from the progress made clinically, it has provided opportunity for me to add about a third to my holdings and I’m comfortable with that and have patience to await final readout of P1a, mid year. Granted there are shareholders who have much higher averages and have concerns but I believe that we’re not far off from being on a firmer footing. The BOD acted quickly after the MHRA debacle to pivot to Aus, I’m prepared to give them the benefit of the doubt to sort a new source of funding to replace RF and then imo it’s really game on.
Have a good weekend , GLA
Hi Gunner,
My understanding, from one of the presentations, I think it was Tim that mentioned that successful P1a progression of 1801 through the safety part of the trial , would negate the need for same with 1802 and that administration could proceed directly with patients . That’s my recollection, I stand open to correction though.
Evening all,
Just a few munterings as T2 used to say.
I’m here invested here approaching 4 yrs now, a ‘newcomer’ some might say ! Average buy-in about the 1p mark, old money. My initial investment was made on the basis of the value I saw then for a company involved in studies in both autoimmune and oncology research. I took a medium term view, prepared to await the opportunity to get into trials.
The company have stated, in my time invested anyhow, that the aim was to deal/ licence at pre/ early clinical. If I was willing to invest back then, with the molecules only at lab stage then with the progress to clinic now, I’m more comfortable now with P1a at /nearing it’s completion, before the data readout. As SOG has clearly highlighted the importance of this final Biomarker part of the phase, in a recent post, we eagerly await the successful conclusion and hopeful progression to P1b.
The BOD still advise that the trial is proceeding so, as the SP hovers at these levels,given where we are now, I believe the disconnect to be greater than ever before and hence I’ve been a buyer over the last fortnight, at levels I honestly didn’t think I would get to avail of again.
I also believe interest from prospective partners/ suitors and will increase markedly if the safety box has been ticked.Remember that 1802 can be administered to patients with confirmation of 1801 safety.How much extra value does that bring ? Finally, I’m always conscious of the fact that there are relatively few shares in SAR at the 72m mark or thereabouts (albeit some more will duly be allocated to RF ) So as daily volumes are tiny at present, positive 1801 safety news will IMO bring new levels of interest and hopefully the SP moves accordingly. 737 is at last licensed and we await news on both the licencee and the pathway forward . Maybe the next piece of news on that front could be receipt of the initial payment due under the terms of the agreement.
GLA, onwards and hopefully soon,Upwards !
Good evening Sad & Luton,
Good news indeed today. Further to both of your points, I would add this. Should this private U.S bio pharma be successful in trial with 737 and things progress as quickly stateside as they have for 1801 in Aus for Sareum then it could get interesting with today’s announcement of the issuance of shares in the licencee company should they seek a public listing or decide to sell out to a large pharma upon successful trial results. A lot to ponder once details become public about the licence deal.
Plenty to look forward to in 2024,especially with updates potentially coming on multiple fronts now. GLA , onwards and upwards
A very Happy & healthy New Year to all invested here. Hoping for positive 1801 news soon. Dose escalation completion and progress towards Ph1b will hopefully flush out interested parties if safety studies are successful. 737 progression would boost both the SP and the coffers and offer a welcome funding alternative for 1801/2 , whilst strengthening our negotiating position. We could wave goodbye to the RF facility, which is an overhang on the SP at the moment. It will be an interesting year for sure.
Best of luck all
AD
Good to see you post C79 and glad all is well with you and that you’re still fully onboard here. Thanks for posting your research. It’s refreshing to read after the back and forth handbags stuff of late. As you say, regular posters should consider using the filter button first, as a response to posters whose intention it is to disrupt . Otherwise , good to see 1801 trials progressing, steadily, methodically and to the timelines outlined.
GLALTH
Hi Citizen, Noticed you haven’t posted in a while. Hope you’re still invested here. Enjoyed all your research and informative posts.
In relation to SP action today , from a small amount of trades I may add, there will always be those who expect announcements at a presentation which haven’t been RNS’d , which cannot happen. For those traders, I’d suggest a visit to the bookies, plenty of racing on today, if it’s a quick doubler you’re after. This is pharma, which must go through the process and that takes time, doesn’t happen overnight
Presentation today was as expected. BOD cautiously prudent on timelines which is the correct approach imo, better to surprise to the upside. As stated definite timeframes dependent on factors beyond SAR control re recruitment of subjects and clinic capacity but Aus thus far has proven an efficient place to trial from what we’ve seen.
To Abers point, steady progress of 1801 in clinic to date, IMO will be focusing minds at large pharmas anxious to get ahead of competitors. I believe some sort of arrangement, be it licence/ T/O will happen before the end of p1b as 1801 is progressing well through the clinic and the TYK2 JAK1 space is hot right now. No large pharma will want to be left behind its competitors in taking advantage of such a proposition ( obv subject to positive/ continued progress in efficacy).
Finally, great , concise summary of the presentation there Laz2. GLALTH
Like yourself Leggster, I too am feeling positive about next week. Alongside FY financial results it would be great to see a positive update on progress from the clinic. The SP seems reasonably stable at the moment about the 80p mark, albeit disappointing for shareholders. I’ve squirrelled away another 10k over the last 2 weeks as I think back to money raised in June ‘21 at 2.8p old money and can’t help but feel SAR very undervalued considering where things are now, notwithstanding the setbacks in the interim. Maybe RF will hold into a rise as you say. The IMC Wednesday will be interesting and hopefully a floor on the SP.
GLALTH
HBD, I remember that figure also being mentioned by Tim at one of the Investor Meets presentations and if memory serves me right, he clarified it further by saying it was for each molecule.
Onwards and upwards !
As per latest RNS, SDC1801 is progressing well through trial. IMO news will come soon on escalation dosing. September I believe will be interesting and should provide positive forward momentum. Hence I have been happily nibbling away this morning, adding to my investment here. I’m not here to trade and am quite confident / comfortable with my position in SAR.
GLA
Thanks for posting citizen 79, your factual,research-based are always welcome, particularly as a counter balance to the negativity being spouted by some new arrivals with self serving agendas. Progress in testing certainly validating Tyk2/Jak1 class thus enhancing 1801/1802 prospects.Exciting times ahead if Sar can get beyond the current trial phase and into efficacy evaluation .Then let’s see how we stack up against the opposition.
GLA genuine holders
Leading on from yesterday’s RNS regarding the BOD securing funding for the completion of ph1a/b trials of 1801, we have some new arrivals here eager to portray the view that the BOD aren’t as confident of a positive outcome.Remember, this stage of the trial is to ascertain SAFETY not EFFICACY in HEALTHY subjects !! No RNS has been issued as to progress as yet and as such the trial continues as no safety concerns have been expressed. As SOG has stated a number of times on here that the dosages for the safety bar have been somewhat scaled back which should ensure success in order to proceed to the efficacy stage of the trial. No doubt we’ll see more prophets of doom as we go forward but we kinda expected that.
Patiently waiting and watching and holding , onwards soon to dose escalation/ efficacy and let’s see what we’ve really got here. GLATH
My take on this mornings RNS is that SAR have lined up a significant amount of funding, all of which may not be required depending on progress regarding 737. This is prudent at this juncture to see 1801 through phase 1a/b. This was done before the coffers became too depleted and if 1801 progresses will have an accretive effect on the subsequent value of 1802. I see it as feeding a spratt to catch a salmon. Also the significant tax credit of up to 1.6m on R&D expenses cannot be overestimated. If this mornings funding announcement gets 1801 through 1a/b then the big whale of 1802 comes clearly into view,by which point I would expect SAR would no longer be in private hands.
Great news today .Credit to the Bod for the decisive action to pivot to Aus.Many thanks for the positive and informative posts here by the faithful ! The journey ahead is certainly exciting and gathering momentum now. GLA
Agreed Fearg, definitely the stand out from the RNS for me. A real indication of board confidence in 1801 superiority over current market offerings and those in development. It should be a spur to a deal/licence/partnering sooner rather than later I would imagine.
Great RNS today,worth the wait.Professional,detailed and leaves no doubt in my mind that SAR are highlighting the real commercial possibilities of their excellent TYK2/JAK1 research work thus far . SAR seem quite confident in their molecules capabilities and today’s announcement will undoubtedly bring further investment and possible deals to partner.The FOMO must surely be a reality for BOD’s at a number of pharma companies now, especially if the efficacy of our offering proves superior as trials progress .Well done all that have held,patience is being rewarded, very exiting times ahead . Step by steady step real value being created here ! GLA
Many thanks for your de-brief RMM .Succinctly put and reassuring on the pathway forwards for our molecules
Happy New Year to all .I’ve enjoyed the conversation,discussion and especially the informative posts of the learned.Every day is a school day as they say.Yes,admittedly the SP has fallen back for various reasons but I believe 2022 offers so much potential here and I’m confident in SAR to deliver on the science which will IMO translate into a market cap multiples of where it stands today.I honestly expect to have the opportunity by the end of 2022 to cash in my chips should I wish to.The board have steadfastly enhanced the SAR offering over this past year through funds raised,patents and progress with the molecules.Agreed SOG,further funds will probably be required for the next levels but therein lies the prospect of an exciting year ahead.Again HNY to all,wishing good health and prosperity.Augustdestiny